The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen

• Published in: Annals of hematology 2021-07, Vol.100 (7), p.1879-1889
• Main Authors: Ke, Peng, Zhang, Xinyou, Liu, Songbai, Zhu, Qian, Ma, Xiao, Chen, Feng, Tang, Xiaowen, Han, Yue, Fu, ZhengZheng, Chen, Suning, Wu, Depei, Qiu, Huiying, Zhou, Jihao, Bao, Xiebing
• Format: Article
• Language: English
• Subjects: Epstein-Barr virus; Hematology; Leukemia; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Original Article; Stem cell transplantation; Transplants & implants
• ISSN: 0939-5555; 1432-0584
• DOI: 10.1007/s00277-021-04528-6

Epstein-Barr virus (EBV) viremia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The purpose of this study was to evaluate the impacts of early-onset EBV viremia in acute leukemia (AL) patients who underwent allo-HSCT with anti-thymocyte globulin (ATG)-containing myeloablative conditioning (MAC) regimen. Two hundred and ninety-six patients were included between January 2013 and December 2015. In 126 patients (42.6%) who developed early-onset EBV viremia, with a median time of 48 (range 18~99) days after allo-HSCT. The cumulative incidence of EBV viremia at 30 and 90 days after allo-HSCT were 4.1 and 39.9%, respectively. Prognostic analysis showed that the adjusted overall survival in early-EBV pos group was significantly lower than early-EBV neg group within the first 26.7 months after allo-HSCT [hazard ratio (HR), 1.63, P = 0.012], but significantly higher than those afterward (after 26.7 months: HR 0.11, P = 0.035); for the adjusted event-free survival, early-EBV pos group was significantly inferior in early-EBV pos group within the first 10.8 months after transplantation (HR: 1.55, P = 0.042), and this adverse effect was not detected any more after 10.8 months (HR: 0.58, P = 0.107). Compared with early-EBV neg group after adjusting by aGVHD and CMV viremia, HR for death from transplant-related mortality was 2.78-fold higher in patients with early-EBV viremia in piecewise constant Cox analysis ( P = 0.006), and this adverse effect was not detected any more after the cut-point time (HR: 0.67, P = 0.361). No differences in terms of relapse and relapse mortality were observed between early-EBV pos and early-EBV neg group ( P > 0.05). In conclusion, the impacts on transplant outcomes of early-EBV viremia were time-dependent, which may help to optimize management strategies for early-EBV viremia after allo-HSCT, especially in AL patients with ATG-containing MAC regimen.